Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study
Clinical Infectious Diseases — Benfield T, Bodilsen J, Brieghel C, et al. | June 11, 2021
In this study, the efficacy of standard of care (SOC) alone vs SOC plus remdesivir and dexamethasone was compared. Researchers enrolled two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020. They compared death within 30 days and need of mechanical ventilation (MV) by inverse probability of treatment weighted logistic regression analysis and shown as odds ratio with 95% confidence interval. This study’s findings demonstrate that treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was correlated with decreased 30-day mortality and need of MV in comparison with treatment in February through May.